[go: up one dir, main page]

MA26905A1 - Derives de phenylglycine. - Google Patents

Derives de phenylglycine.

Info

Publication number
MA26905A1
MA26905A1 MA26921A MA26921A MA26905A1 MA 26905 A1 MA26905 A1 MA 26905A1 MA 26921 A MA26921 A MA 26921A MA 26921 A MA26921 A MA 26921A MA 26905 A1 MA26905 A1 MA 26905A1
Authority
MA
Morocco
Prior art keywords
derivatives
phenylglycin
physiologically acceptable
carbamimidoyl
solvates
Prior art date
Application number
MA26921A
Other languages
English (en)
Inventor
Leo Alig
Zbinden Katrin Groebke
Kurt Hilpert
Holger Kuehne
Ulrike Obst
Hans Peter Wessel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26905A1 publication Critical patent/MA26905A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
MA26921A 2000-05-23 2002-11-22 Derives de phenylglycine. MA26905A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110881 2000-05-23

Publications (1)

Publication Number Publication Date
MA26905A1 true MA26905A1 (fr) 2004-12-20

Family

ID=8168800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26921A MA26905A1 (fr) 2000-05-23 2002-11-22 Derives de phenylglycine.

Country Status (23)

Country Link
US (1) US6548694B2 (fr)
EP (1) EP1289939A1 (fr)
JP (1) JP3842132B2 (fr)
KR (1) KR100569517B1 (fr)
CN (1) CN1305839C (fr)
AR (1) AR028596A1 (fr)
AU (2) AU2001281774B2 (fr)
BR (1) BR0110998A (fr)
CA (1) CA2408602C (fr)
EC (1) ECSP024360A (fr)
HU (1) HUP0302073A2 (fr)
IL (1) IL152581A0 (fr)
MA (1) MA26905A1 (fr)
MX (1) MXPA02011466A (fr)
NO (1) NO20025590L (fr)
NZ (1) NZ522412A (fr)
PE (1) PE20011314A1 (fr)
PL (1) PL361355A1 (fr)
RU (1) RU2268257C2 (fr)
UY (1) UY26721A1 (fr)
WO (1) WO2001090051A1 (fr)
YU (1) YU83602A (fr)
ZA (1) ZA200208899B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245381C (zh) * 1998-12-14 2006-03-15 弗·哈夫曼-拉罗切有限公司 苯基甘氨酸衍生物
DE10300049A1 (de) * 2003-01-03 2004-07-15 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Faktor VIIa inhibieren
US6642386B2 (en) 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
GB0211931D0 (en) * 2002-05-23 2002-07-03 Univ Liverpool Methods & device utilizing adsorption of molecules at a surface or interface
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
EP1594505A4 (fr) 2003-02-11 2008-08-13 Bristol Myers Squibb Co Derives de phenylglycine utiles en tant qu'inhibiteurs de serine protease
JP2006517589A (ja) 2003-02-11 2006-07-27 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ・インヒビターとして有用なベンゼンアセトアミド化合物
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
US7917130B1 (en) 2003-03-21 2011-03-29 Stratosaudio, Inc. Broadcast response method and system
US7776804B2 (en) * 2005-03-16 2010-08-17 The Lubrizol Corporation Viscosity improver compositions providing improved low temperature characteristics to lubricating oil
US7056932B2 (en) * 2003-12-19 2006-06-06 Hoffman-La Roche Inc. Heterocyclyl substituted 1-alkoxy acetic acid amides
US20080132507A1 (en) * 2004-10-13 2008-06-05 Eisai R&D Management Co., Ltd. Hydrazide Derivatives
WO2006045096A2 (fr) * 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoides et isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires
DE602006016566D1 (de) 2005-01-10 2010-10-14 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE455103T1 (de) * 2005-06-24 2010-01-15 Bristol Myers Squibb Co Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
US8044242B2 (en) 2006-03-09 2011-10-25 Bristol-Myers Squibb Company 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants
PL2000465T3 (pl) * 2006-03-24 2011-05-31 Eisai R&D Man Co Ltd Pochodna triazolonu
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
EP1967522A1 (fr) * 2007-03-07 2008-09-10 Novo Nordisk A/S Nouveaux inhibiteurs de coagulation sanguine
EP2202231A4 (fr) * 2007-09-21 2011-09-28 Eisai R&D Man Co Ltd Dérivé de 2,3-dihydroiminoisoindole
WO2009079417A1 (fr) 2007-12-14 2009-06-25 Stratosaudio, Inc. Systèmes et procédés de programmation de supports et d'événements interactifs
KR101629356B1 (ko) * 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
WO2010106436A2 (fr) 2009-03-18 2010-09-23 Resverlogix Corp. Nouveaux agents anti-inflammatoires
TR201818390T4 (tr) 2009-04-22 2019-01-21 Resverlogix Corp Yeni̇ anti̇-i̇nflamatuvar ajanlar
CN102887836B (zh) * 2011-07-18 2014-03-26 西南大学 L-苯甘氨酸衍生物及其应用
TR201909777T4 (tr) 2011-11-01 2019-07-22 Resverlogix Corp Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar
GB201118876D0 (en) * 2011-11-01 2011-12-14 Astex Therapeutics Ltd Pharmaceutical compounds
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014096965A2 (fr) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN111072562B (zh) * 2019-11-07 2021-12-07 中山大学 一种四氢异喹啉衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008116C (fr) * 1989-02-23 2001-11-20 Thomas Weller Derives de glycine
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
DE59808751D1 (de) 1997-12-04 2003-07-24 Hoffmann La Roche N-(4-carbamimido-phenyl)-glycinamidderivate
EP1078917A4 (fr) 1998-02-17 2002-11-06 Ono Pharmaceutical Co Derives amidino utilises comme ingredients actifs et medicaments les contenant
CN1245381C (zh) * 1998-12-14 2006-03-15 弗·哈夫曼-拉罗切有限公司 苯基甘氨酸衍生物

Also Published As

Publication number Publication date
US20020004608A1 (en) 2002-01-10
HUP0302073A2 (hu) 2003-09-29
AR028596A1 (es) 2003-05-14
EP1289939A1 (fr) 2003-03-12
NO20025590D0 (no) 2002-11-21
CN1305839C (zh) 2007-03-21
NZ522412A (en) 2004-05-28
CA2408602C (fr) 2008-01-08
IL152581A0 (en) 2003-05-29
CN1430599A (zh) 2003-07-16
PL361355A1 (en) 2004-10-04
RU2268257C2 (ru) 2006-01-20
AU8177401A (en) 2001-12-03
US6548694B2 (en) 2003-04-15
KR100569517B1 (ko) 2006-04-07
NO20025590L (no) 2002-11-21
KR20030007678A (ko) 2003-01-23
JP2003534311A (ja) 2003-11-18
UY26721A1 (es) 2001-12-28
JP3842132B2 (ja) 2006-11-08
YU83602A (sh) 2006-05-25
BR0110998A (pt) 2003-04-08
CA2408602A1 (fr) 2001-11-29
ZA200208899B (en) 2004-02-19
PE20011314A1 (es) 2002-01-04
AU2001281774B2 (en) 2005-03-10
WO2001090051A1 (fr) 2001-11-29
MXPA02011466A (es) 2003-04-25
ECSP024360A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
MA26905A1 (fr) Derives de phenylglycine.
PT1193270E (pt) Pirrolobenzodiazepinas
ATE302775T1 (de) Carbolinderivate
TR200101744T2 (tr) Fenilglisin türevleri.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
CO5210911A1 (es) Trifluorbutenos nematicidas
DK0944643T3 (da) Oxyiminopregnancarbolactoner.
ATE346067T1 (de) Carbolinderivate
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
TW200502231A (en) Prodrugs of proton pump inhibitors
MXPA05009282A (es) Derivados de anilina sustituidos.
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE259813T1 (de) Triazolopyrimidinderivate
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
PT1204659E (pt) Benzofuranos serotoninergicos
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
DE60124245D1 (de) Uridinderivate als antibiotika
TR200200017T2 (tr) Benzofuran türevleri
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
IS8034A (is) Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla
EA200600249A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
SG145573A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
ECSP993261A (es) Derivados de fenilglicina